Relative ADC and Location Differ between Posterior Fossa Pilocytic Astrocytomas with and without Gangliocytic Differentiation

References

1. 1.↵
   2. Brandner S,
   3. von Deimling A

   . Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathol Appl Neurobiol 2015;41:694–720 doi:10.1111/nan.12246 pmid:25944653

   CrossRefPubMed
2. 2.↵
   2. Dougherty MJ,
   3. Santi M,
   4. Brose MS, et al

   . Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010;12:621–30 doi:10.1093/neuonc/noq007 pmid:20156809

   Abstract/FREE Full Text
3. 3.↵
   2. Tatevossian RG,
   3. Lawson AR,
   4. Forshew T, et al

   . MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol 2010;222:509–14 doi:10.1002/jcp.21978 pmid:19937730

   CrossRefPubMed
4. 4.↵
   2. Dhillon AS,
   3. Hagan S,
   4. Rath O, et al

   . MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279–90 doi:10.1038/sj.onc.1210421 pmid:17496922

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Schindler G,
   3. Capper D,
   4. Meyer J, et al

   . Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397–405 doi:10.1007/s00401-011-0802-6 pmid:21274720

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Korshunov A,
   3. Meyer J,
   4. Capper D, et al

   . Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009;118:401–05 doi:10.1007/s00401-009-0550-z pmid:19543740

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Poretti A,
   3. Meoded A,
   4. Huisman TA

   . Neuroimaging of pediatric posterior fossa tumors including review of the literature. J Magn Reson Imaging 2012;35:32–47 doi:10.1002/jmri.22722 pmid:21989968

   CrossRefPubMed
8. 8.↵
   2. Koeller KK,
   3. Rushing EJ

   . From the archives of the AFIP: pilocytic astrocytoma—radiologic-pathologic correlation. Radiographics 2004;24:1693–708 doi:10.1148/rg.246045146 pmid:15537977

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Fisher PG,
   3. Tihan T,
   4. Goldthwaite PT, et al

   . Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 2008;51:245–50 doi:10.1002/pbc.21563 pmid:18386785

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Stokland T,
    3. Liu JF,
    4. Ironside JW, et al

    . A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol 2010;12:1257–68 doi:10.1093/neuonc/noq092 pmid:20861086

    Abstract/FREE Full Text
11. 11.↵
    2. Chang T,
    3. Teng MM,
    4. Lirng JF

    . Posterior cranial fossa tumours in childhood. Neuroradiology 1993;35:274–78 doi:10.1007/BF00602613 pmid:8492893

    CrossRefPubMed
12. 12.↵
    2. Dudley RW,
    3. Torok MR,
    4. Gallegos DR, et al

    . Pediatric low-grade ganglioglioma: epidemiology, treatments, and outcome analysis on 348 children from the surveillance, epidemiology, and end results database. Neurosurgery 2015;76:313–19; discussion 319; quiz 319–20 doi:10.1227/NEU.0000000000000619 pmid:25603107

    CrossRefPubMed
13. 13.↵
    2. Rickert CH,
    3. Paulus W

    . Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 2001;17:503–11 doi:10.1007/s003810100496 pmid:11585322

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Koelsche C,
    3. Wöhrer A,
    4. Jeibmann A, et al

    . Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013;125:891–900 doi:10.1007/s00401-013-1100-2 pmid:23435618

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Qaddoumi I,
    3. Orisme W,
    4. Wen J, et al

    . Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 2016;131:833–45 doi:10.1007/s00401-016-1539-z pmid:26810070

    CrossRefPubMed
16. 16.↵
    2. Compton JJ,
    3. Laack NN,
    4. Eckel LJ, et al

    . Long-term outcomes for low-grade intracranial ganglioglioma: 30-year experience from the Mayo Clinic. J Neurosurg 2012;117:825–30 doi:10.3171/2012.7.JNS111260 pmid:22957524

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Lindsay AJ,
    3. Rush SZ,
    4. Fenton LZ

    . Pediatric posterior fossa ganglioglioma: unique MRI features and correlation with BRAF V600E mutation status. J Neurooncol 2014;118:395–404 doi:10.1007/s11060-014-1450-1 pmid:24792487

    CrossRefPubMed
18. 18.↵
    2. Castillo M,
    3. Davis PC,
    4. Takei Y, et al

    . Intracranial ganglioglioma: MR, CT, and clinical findings in 18 patients. AJR Am J Roentgenol 1990;154:607–12 doi:10.2214/ajr.154.3.2106228 pmid:2106228

    CrossRefPubMed
19. 19.↵
    2. Safavi-Abbasi S,
    3. Di Rocco F,
    4. Chantra K, et al

    . Posterior cranial fossa gangliogliomas. Skull Base 2007;17:253–64 doi:10.1055/s-2007-984486 pmid:18174926

    CrossRefPubMed
20. 20.↵
    2. Zhang D,
    3. Henning TD,
    4. Zou LG, et al

    . Intracranial ganglioglioma: clinicopathological and MRI findings in 16 patients. Clin Radiol 2008;63:80–91 doi:10.1016/j.crad.2007.06.010 pmid:18068794

    CrossRefPubMed
21. 21.↵
    2. Gupta K,
    3. Orisme W,
    4. Harreld JH, et al

    . Posterior fossa and spinal gangliogliomas form two distinct clinicopathologic and molecular subgroups. Acta Neuropathol Commun 2014;2:18 doi:10.1186/2051-5960-2-18 pmid:24529209

    CrossRefPubMed
22. 22.↵
    2. Koral K,
    3. Alford R,
    4. Choudhury N, et al

    . Applicability of apparent diffusion coefficient ratios in preoperative diagnosis of common pediatric cerebellar tumors across two institutions. Neuroradiology 2014;56:781–88 doi:10.1007/s00234-014-1398-z pmid:24974083

    CrossRefPubMed
23. 23.↵
    2. Forshew T,
    3. Tatevossian RG,
    4. Lawson AR, et al

    . Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009;218:172–81 doi:10.1002/path.2558 pmid:19373855

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Bannykh SI,
    3. Mirocha J,
    4. Nuno M, et al

    . V600E BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior. Clin Neuropathol 2014;33:388–98 doi:10.5414/NP300753 pmid:25066317

    CrossRefPubMed
25. 25.↵
    2. Hawkins C,
    3. Walker E,
    4. Mohamed N, et al

    . BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 2011;17:4790–98 doi:10.1158/1078-0432.CCR-11-0034 pmid:21610142

    Abstract/FREE Full Text
26. 26.↵
    2. Horbinski C,
    3. Hamilton RL,
    4. Nikiforov Y, et al

    . Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 2010;119:641–49 doi:10.1007/s00401-009-0634-9 pmid:20044755

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Koelsche C,
    3. Sahm F,
    4. Wöhrer A, et al

    . BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Brain Pathol 2014;24:221–29 doi:10.1111/bpa.12111 pmid:24345274

    CrossRefPubMed
28. 28.↵
    2. Sievert AJ,
    3. Lang SS,
    4. Boucher KL, et al

    . Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 2013;110:5957–62 doi:10.1073/pnas.1219232110 pmid:23533272

    Abstract/FREE Full Text
29. 29.↵
    2. Hatzivassiliou G,
    3. Song K,
    4. Yen I, et al

    . RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431–35 doi:10.1038/nature08833 pmid:20130576

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Rodriguez FJ,
    3. Ligon AH,
    4. Horkayne-Szakaly I, et al

    . BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol 2012;71:789–94 doi:10.1097/NEN.0b013e3182656ef8 pmid:22892521

    CrossRefPubMed
31. 31.↵
    2. Jones DT,
    3. Kocialkowski S,
    4. Liu L, et al

    . Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68:8673–77 doi:10.1158/0008-5472.CAN-08-2097 pmid:18974108

    Abstract/FREE Full Text
32. 32.↵
    2. Pollack IF,
    3. Jakacki RI

    . Childhood brain tumors: epidemiology, current management and future directions. Nat Rev Neurol 2011;7:495–506 doi:10.1038/nrneurol.2011.110 pmid:21788981

    CrossRefPubMed
33. 33.↵
    2. Dahiya S,
    3. Haydon DH,
    4. Alvarado D, et al

    . BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 2013;125:901–10 doi:10.1007/s00401-013-1120-y pmid:23609006

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Burkhard C,
    3. Di Patre PL,
    4. Schüler D, et al

    . A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg 2003;98:1170–74 doi:10.3171/jns.2003.98.6.1170 pmid:12816259

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Lang FF,
    3. Epstein FJ,
    4. Ransohoff J, et al

    . Central nervous system gangliogliomas: part 2, clinical outcome. J Neurosurg 1993;79:867–73 doi:10.3171/jns.1993.79.6.0867 pmid:8246055

    CrossRefPubMedWeb of Science
36. 36.↵
    2. Miller DC,
    3. Lang FF,
    4. Epstein FJ

    . Central nervous system gangliogliomas: part 1, pathology. J Neurosurg 1993;79:859–66 doi:10.3171/jns.1993.79.6.0859 pmid:8246054

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Malyarenko DI,
    3. Newitt D,
    4. Wilmes LJ, et al

    . Demonstration of nonlinearity bias in the measurement of the apparent diffusion coefficient in multicenter trials. Magn Reson Med 2016;75:1312–23 doi:10.1002/mrm.25754 pmid:25940607

    CrossRefPubMed
38. 38.↵
    2. Sasaki M,
    3. Yamada K,
    4. Watanabe Y, et al

    ; Acute Stroke Imaging Standardization Group-Japan (ASIST-Japan) Investigators. Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. Radiology 2008;249:624–30 doi:10.1148/radiol.2492071681 pmid:18936317

    CrossRefPubMed
39. 39.↵
    2. Jenkinson MD,
    3. Smith TS,
    4. Brodbelt AR, et al

    . Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging 2007;26:1405–12 doi:10.1002/jmri.21062 pmid:17968881

    CrossRefPubMed
40. 40.↵
    2. Rodriguez Gutierrez D,
    3. Awwad A,
    4. Meijer L, et al

    . Metrics and textural features of MRI diffusion to improve classification of pediatric posterior fossa tumors. AJNR Am J Neuroradiol 2014;35:1009–15 doi:10.3174/ajnr.A3784 pmid:24309122

    Abstract/FREE Full Text